Once valued at $9B, Theranos to close

Amy Baxter | | Health Exec | Precision Medicine
6638074343_dab655b246_b.jpg

Theranos, the Silicon Valley-based blood-testing startup that was once valued at $9 billion, is dissolving. The company has been clad in scandal after reports revealed Theranos’ trademark service­–to test blood with a single pinprick–wasn’t effective or accurate.

Its founder, Elizabeth Holmes, once heralded as the next Steve Jobs by Inc. Magazine, and Sunny Balwani, Theranos’s former president and COO, are facing criminal charges for defrauding investors out of hundreds of millions of dollars.

The Washington Post first reported the story on the company’s closure, which was detailed in a note to shareholders issued Monday by CEO and General Counsel David Taylor. Theranos will pay its creditors after turning over its assets and intellectual property to Fortress, a credit and investment firm.

The move will leave Theranos with $5 million to pay creditors. It owes more than $60 million.

Read the full story below:

Blood-testing company Theranos will dissolve, pay creditors

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Design by Adaptive Theme
Trimed Popup
Trimed Popup